Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DSGN
DESIGN THERAPEUTICS, INC.
NASDAQ
$15.11
▼ DOWN 0.92% (-0.14)

KEY STATISTICS

Market Cap$943.73 M
52w High$17.25
52w Low$5.28
Dividend Yield—
Frequency—
P/E-12.81
Volume820.75K
Shares Out.62.46M

COMPANY

LEADERSHIP

Pratik Shah
CHIEF EXECUTIVE
Pratik Shah

COMPENSATION 2026

Salary$395,000
Stock Awards$0
Incentive Plan Pay$237,000
All Other Comp.$14,000
Total$3,544,300

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 29, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
55

PRICE TARGET

Target High$21.00
Target Low$20.00
Target Median$20.50
Target Consensus$20.50

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.—
NOV
4
WED

PRICE

$15.11 ▼ DOWN 0.92% (−$0.14)
$14.85$15.00$15.15$15.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM15.11

About Design Therapeutics, Inc.

https://www.designtx.com ↗

Design Therapeutics, Inc. is a preclinical biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions, including Friedreich Ataxia, Myotonic Dystrophy Type-1, and other monogenic disorders.

INDUSTRY

Biotechnology

A SERVICE DESIGN THERAPEUTICS, INC. IS KNOWN FOR

GeneTAC® (Gene Targeted Chimera) Platform for Therapeutic Development

A proprietary platform developing GeneTACs, small molecule medicines that target genetic causes of inherited diseases to modify gene expression and provide disease-modifying treatments.

COMPETITORS

COMPETITOR
ARWR COMPARE
IONS COMPARE
LRMR COMPARE
PTCT COMPARE
WVE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
81
LISTED HERE
15
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.2M
IWM
0.02% · 805.7K
FESM
0.05% · 234.8K
DFAS
0.02% · 156.2K
SCHA
0.01% · 153.8K
SBIO
0.48% · 77.3K
ZPRR.DE
0.02% · 65.5K
BBC
0.83% · 28.6K
XRS2.DE
0.01% · 28.1K
GSSC
0.04% · 26.4K
RSSL
0.01% · 14.6K
AVSC
0.01% · 14.0K
IBBQ
0.06% · 3.9K
BIB
0.03% · 2.2K
RESM
0.02% · 74

INSTITUTIONAL OWNERSHIP

SHARES OWNED
58.66%
HOLDERS
227
TOP 12 OF 227 · RANKED BY POSITION SIZE
Sr One Capital Management, LP
6.5M sh · $49.14M
Point72 Asset Management, L.P.
5.4M sh · $50.39M
Logos Global Management LP
3.7M sh · $27.52M
Ra Capital Management, L.P.
3.0M sh · $31.63M
Baker Bros. Advisors LP
2.7M sh · $38.76M
Driehaus Capital Management LLC
2.7M sh · $38.51M
Blackrock, Inc.
2.7M sh · $38.49M
Connor Clark & Lunn Investment Management Ltd
2.4M sh · $34.69M
Blackrock Inc.
2.3M sh · $7.72M
Frazier Life Sciences Management, L.P.
2.0M sh · $14.71M
Tang Capital Management LLC
1.8M sh · $13.41M
Vanguard Group Inc
1.6M sh · $15.3M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Gover Justin D.
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
Berger Heather A.
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
Shapiro David
Purchase · 30.0K shares
2026-06-09
★
DIRECTOR
Schmid John P.
Purchase · 30.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 3
3 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM RBC Capital OUTPERFORM Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
ANNX$4.97COMPARE
AURA$7.40COMPARE
ALT$3.11COMPARE
RCKT$3.86COMPARE
DMAC$6.39COMPARE
GALT$4.02COMPARE
KRRO$12.91COMPARE